Edgewise Therapeutics (EWTX) Interest & Investment Income (2020 - 2026)
Edgewise Therapeutics (EWTX) reported Interest & Investment Income of $5.1 million for Q1 2026, down 1.14% on a YoY basis from $5.2 million in Q1 2025, and down 11.47% sequentially from $5.8 million in Q4 2025.
Edgewise Therapeutics (EWTX) Interest & Investment Income (2020 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 7 years of Interest & Investment Income data on file, last reported at $5.1 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 1.14% year-over-year to $5.1 million; the trailing twelve-month figure through Mar 2026 stood at $23.6 million (down 1.67% YoY), and the FY2025 full-year result was $23.6 million, down 5.63% from the prior year.
- Interest & Investment Income retreated to $5.1 million in Q1 2026, from $5.8 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $6.6 million in Q2 2024 to a low of $166000.0 in Q1 2022.
- A 5-year average of $4.2 million and a median of $5.1 million in 2026 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income surged 2014.29% in 2022 and slipped 17.13% in 2025, its largest moves.
- Tracing EWTX's Interest & Investment Income over 5 years: stood at $2.7 million in 2022, then jumped by 39.6% to $3.7 million in 2023, then jumped by 58.05% to $5.9 million in 2024, then declined by 1.96% to $5.8 million in 2025, then fell by 11.47% to $5.1 million in 2026.
- Business Quant data shows EWTX's Interest & Investment Income at $5.1 million in Q1 2026, $5.8 million in Q4 2025, and $6.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Edgewise Therapeutics | 4.37 Bn | 4.37 Bn | - | 5.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.10 Mn |
| Dec 31, 2025 | 5.76 Mn |
| Sep 30, 2025 | 6.19 Mn |
| Jun 30, 2025 | 6.50 Mn |
| Mar 31, 2025 | 5.16 Mn |
| Dec 31, 2024 | 5.88 Mn |
| Sep 30, 2024 | 6.30 Mn |
| Jun 30, 2024 | 6.61 Mn |
| Mar 31, 2024 | 6.23 Mn |
| Dec 31, 2023 | 3.72 Mn |
| Sep 30, 2023 | 3.74 Mn |
| Jun 30, 2023 | 3.87 Mn |
| Mar 31, 2023 | 2.87 Mn |
| Dec 31, 2022 | 2.66 Mn |
| Sep 30, 2022 | 764,000.00 |
| Jun 30, 2022 | 424,000.00 |
| Mar 31, 2022 | 166,000.00 |
| Dec 31, 2021 | 126,000.00 |
| Sep 30, 2021 | 127,000.00 |
| Jun 30, 2021 | 107,000.00 |